Private Equity PE Fund Investments
API maker Natural BioGenex raises Rs.18.61 Cr from Somerset Indus Capital
Source Indian Pharma Post (opens in a new tab)BSE Announcement (opens in a new tab)
Healthcare-focused private equity fund Somerset Indus Capital Partners has invested INR 18.61 crore in Natural BioGenex Pvt Ltd (NBPL), a Bengaluru-based unlisted subsidiary of publicly listed Natural Capsules Ltd (NCL) at a pre-money valuation of INR 250 crore. Phillip Capital India facilitated the investment. The total investment is envisaged to be INR 75 crore.
NBPL is constructing a greenfield facility in Tumkur, near Bengaluru to manufacture active pharmaceutical ingredients (APIs), including Betamethasone, Dexamethasone, and Prednisolone, along with their intermediates and derivatives.